Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Net Margin (2016 - 2025)

Ptc Therapeutics has reported Net Margin over the past 14 years, most recently at 834.08% for Q4 2025.

  • Quarterly results put Net Margin at 834.08% for Q4 2025, down 80317.0% from a year ago — trailing twelve months through Dec 2025 was 32.12% (up 2647.0% YoY), and the annual figure for FY2025 was 32.12%, up 1291.0%.
  • Net Margin for Q4 2025 was 834.08% at Ptc Therapeutics, down from 7.53% in the prior quarter.
  • Over the last five years, Net Margin for PTCT hit a ceiling of 73.68% in Q1 2025 and a floor of 834.08% in Q4 2025.
  • Median Net Margin over the past 5 years was 67.64% (2023), compared with a mean of 100.81%.
  • Biggest five-year swings in Net Margin: skyrocketed 13968bps in 2021 and later crashed -80317bps in 2025.
  • Ptc Therapeutics' Net Margin stood at 86.71% in 2021, then dropped by -18bps to 102.08% in 2022, then skyrocketed by 50bps to 50.74% in 2023, then skyrocketed by 39bps to 30.91% in 2024, then crashed by -2599bps to 834.08% in 2025.
  • The last three reported values for Net Margin were 834.08% (Q4 2025), 7.53% (Q3 2025), and 36.25% (Q2 2025) per Business Quant data.